Palivizumab

Palivizumab was consistently found to be cost-effective as prophylaxis for respiratory syncytial virus disease among neonates on four continents, according to a study presented at the Pediatric Academic Societies Meeting.

Day care attendance in the first 3 years of life was linked to increased risk for lung complications among preterm-born children who were diagnosed with bronchopulmonary dysplasia, according to findings published in Journal of Pediatrics.